Evaluation of serum perlecan levels in pregnancy with mild and severe preeclampsia

Year 2021, Volume: 4 Issue: 5, 538 - 542, 05.09.2021

Ugurkan Erkayıran , Abdullah Tok , Selim Karaküçük , Muhammed Seyithanoğlu , Tufan Arslanca

https://doi.org/10.32322/jhsm.913654

Abstract

Aim: To determine the levels of perlecan, which contributes to autophagy inhibition and angiogenesis, in severe and mild preeclamptic women.
Material and Method: A total of 89 patients including severe preeclampsia, group 1 (n: 30), mild preeeclampsia, group 2 (n: 30) and control group, group 3 (n: 29) were included in the study.
Results: All three groups were evaluated in terms of perlecan levels. Perlecan level in group 1 was determined at higher levels than other groups, and this level difference was statistically significant compared to the other two groups (p <0.0001). Group 2 was found to be significantly higher in favor of group 2 when compared with the control group (p <0.0001). Considering the distribution and average values of the Perlecan level among the groups, 2.43 ng / ml in group 1, 1.22 ng / ml in group 2 and 0.89 ng / ml in the control group were detected. In the correlation of perlecan level with hematological parameters, we found that systolic blood pressure, diastolic blood pressure, AST, ALT, creatinine, proteinuria, and LDH levels were positively correlated with perlecan level in the severe preeclampsia group.
Conclusion: In our study, we found that serum perlecan levels were higher in preeclamptic pregnant women and this increased more especially in those with severe preeclampsia clinic.

Keywords

Perlecan, preeclampsia, autophagy, angiogenesis, pathophysiology

References

• El-Sayed AAF. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements. Taiwanese J Obstet Gynecol 2017; 56: 593-8.
• Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170: 1-7.
• Oh SY, Hwang JR, Choi M, et al. Autophagy regulates trophoblast invasion by targeting NF-κB activity. Scientific Reports Sci Rep.2020; 10: 14033.
• Nakashima A, Aoki A, Kusabiraki T, Cheng SB, Sharma S, Saito S. Autophagy regulation in preeclampsia: Pros and cons. Journal of Reproductive Immunology 2017; 123: 17-23.
• Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the “chickenand-egg” question, Endocrinology 2004; 145: 4835-7.
• Smets EML, Visser, Go ATJI, Vugt JMGV, Oudejans CBM. Novel biomarkers in preeclampsia. Clin Chim Acta 2006; 364: 22-32.
• Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017; 39: 496-512.
• Nakashima A, Yamanaka-Tatematsu M, Fujita N, et al. Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia. Autophagy 2013; 9: 303-16.
• Kalkat M, Garcia J, Ebrahimi J, et al. Placental autophagy regulation by the BOK-MCL1 rheostat. Autophagy 2013; 9: 2140-53.
• Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003; 51: 1393-410.
• Ning L, Xu Z, Furuya N, Nonaka R, Yamada Y, Arikawa-Hirasawa E. Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle, Matrix Biol 2015; 48: 26-35.
• Gubbiotti MA, Neill T, Iozzo RV. A current view of perlecan in physiology and pathology: A mosaic of functions. Matrix Biol 2017; 57-58: 285-98.
• Vuadens F, Benay C, Crettaz D, et al. Identification of biologic markers of the prematüre rupture of fetal membranes: Proteomic approach. Proteomics 2003; 3: 1521-5.
• Akbas M, Koyuncu FM, Ulkumen BA, Taneli F, Ozdemir H. Maternal serum perlecan levels in women with preeclampsia. Hypertens Pregnancy 2020; 39: 70-6.
• Szenasi NL, Toth E, Balogh A, et al. Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies. PeerJ 2019; 7: e6982.
• Yang WC, Su TH, Yang YC, Chang SC, Chen CY, Chen CP. Altered perlecan expression in placental development and gestational diabetes mellitus. Placenta 2005; 26: 780–8.
• Chui A, Murthi P, Brennecke SP, Ignjatovic V, Monagle PT, Said JM. The expression of placental proteoglycans in pre-eclampsia. Gynecol Obstet Invest 2012; 73: 277-84.
• Zhao H, Gong L, Wu S, et al. The inhibition of protein kinase C β contributes to the pathogenesis of peeclampsia by activating autophagy. EBioMedicine 2020; 56: 102813.
• Du J, Ji Q, Dong L, Meng Y, Xin G. HDAC4 Knockdown Induces Preeclampsia Cell Autophagy and Apoptosis by miR-29b. Reprod Sci 2021; 28: 334-42.
• Cornelius DC, Wallace K. Autophagy in preeclampsia: A new target? EBioMedicine 2020; 57: 102864.
• Wu PH, Lin YT, Chiu YW, et al. The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients. Sci Rep 2021; 11: 3786.
• Melrose J. Perlecan, a modular instructive proteoglycan with diverse functional properties. Int J Biochem Cell Biol 2020; 128: 105849.
• Jansson M, Billing O, Herdenberg C, et al. Expression and circulating levels of perlecan in breast cancer-implications for oestrogen dependent stromal remodeling. J Mammary Gland Biol Neoplasia 2020; 25: 69-77.
• Mishra M, Chandavarkar V, Naik VV, Kale AD. An immunohistochemical study of basement membrane heparan sulfate proteoglycan (perlecan) in oral epithelial dysplasia and squamous cell carcinoma. JOMFP, 2013; 17: 31-5.
• Elgundi Z, Papanicolaou M, Major G, et al. Cancer metastasis: the role of the extracellular matrix and the heparan sulfate proteoglycan perlecan. Front Oncol 2020; 9: 1482.